Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary open-angle glaucoma (including pigmentary or pseudoexfoliative) or ocular hypertension in 1 or both eyes.~* Qualifying intraocular pressure (IOP) in the same eye at the Eligibility 1 and 2 measurements.~Exclusion Criteria:~* Closed/barely open anterior chamber angle or a history of acute angle closure in either eye.~* Anticipate the need to initiate or modify medication (systemic or topical) that is known to affect intraocular pressure (IOP) during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stage 1: PF-04217329 - Lowest Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - Low Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - Middle Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - High Middle Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - High Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-02417329 - Highest Dose (Type: EXPERIMENTAL): None
- Stage 1: PF-04217329 - Vehicle (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Low Dose + Latanoprost Vehicle (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Middle Dose + Latanoprost Vehicle (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - High Dose + Latanoprost Vehicle (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Low Dose + Latanoprost 0.005% (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Middle Dose + Latanoprost 0.005% (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - High Dose + Latanoprost 0.005% (Type: EXPERIMENTAL): None
- Stage 2: PF-04217329 - Vehicle + Latanoprost 0.005% (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).